Vibativ(telavancin)
Vibativ (telavancin) is a small molecule pharmaceutical. Telavancin was first approved as Vibativ on 2009-09-11. It is used to treat bacterial infections, infectious skin diseases, pneumonia, staphylococcal infections, and streptococcal infections in the USA. It has been approved in Europe to treat bacterial pneumonia and cross infection.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Vibativ
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Telavancin hydrochloride
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
VIBATIV | Cumberland Pharmaceuticals | N-022110 RX | 2009-09-11 | 1 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
vibativ | New Drug Application | 2021-01-01 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
bacterial infections | — | D001424 | A49 |
infectious skin diseases | — | D012874 | — |
pneumonia | EFO_0003106 | D011014 | J18 |
staphylococcal infections | — | D013203 | A49.01 |
streptococcal infections | EFO_1001476 | D013290 | — |
Agency Specific
FDA
EMA
No data
HCPCS
Code | Description |
---|---|
J3095 | Injection, telavancin, 10 mg |
Clinical
Clinical Trials
25 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Constipation | D003248 | HP_0002019 | K59.0 | — | 1 | 3 | 2 | 2 | 7 |
Gastroparesis | D018589 | EFO_1000948 | K31.84 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Dyspepsia | D004415 | EFO_0008533 | K30 | — | — | 6 | — | — | 6 |
Irritable bowel syndrome | D043183 | EFO_0000555 | K58 | — | — | 1 | — | 1 | 2 |
Opioid-induced constipation | D000079689 | — | — | 2 | — | — | 2 | ||
Gastroesophageal reflux | D005764 | EFO_0003948 | K21 | — | — | 2 | — | — | 2 |
Heartburn | D006356 | R12 | — | — | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Chronic disease | D002908 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | TELAVANCIN |
INN | telavancin |
Description | Telavancin is a glycopeptide that is vancomycin substituted at position N-3'' by a 2-(decylamino)ethyl group and at position C-29 by a (phosphonomethyl)aminomethyl group. Used as its hydrochloride salt for treatment of adults with complicated skin and skin structure infections caused by bacteria. It has a role as an antibacterial drug and an antimicrobial agent. It is functionally related to a vancomycin. |
Classification | Small molecule |
Drug class | vancomycin-related compounds |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CCCCCCCCCCNCCN[C@@]1(C)C[C@H](O[C@H]2[C@H](Oc3c4cc5cc3Oc3ccc(cc3Cl)[C@@H](O)[C@@H](NC(=O)[C@@H](CC(C)C)NC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]5C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c5cc(O)c(CNCP(=O)(O)O)c(O)c5-c5cc3ccc5O)[C@H](O)c3ccc(c(Cl)c3)O4)O[C@H](CO)[C@@H](O)[C@@H]2O)O[C@@H](C)[C@H]1O |
Identifiers
PDB | — |
CAS-ID | 372151-71-8 |
RxCUI | 473837 |
ChEMBL ID | CHEMBL507870 |
ChEBI ID | 71229 |
PubChem CID | 3081362 |
DrugBank | DB06402 |
UNII ID | XK134822Z0 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Vibativ - Cumberland Pharmaceuticals
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Vibativ - Innoviva, Inc.
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,501 documents
View more details
Safety
Black-box Warning
Black-box warning for: Vibativ
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
4,568 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more